Synapse Open Synapse
Biology

A comprehensive analysis of CBER experience with AAV gene therapy IND submissions

Nature Biotechnology ·

An analysis of Investigational New Drug (IND) submissions to the US Food and Drug Administration (FDA) from 1995 to 2025 reveals a rapid growth in adeno-associated virus (AAV) development over three decades and highlights common reasons for regulatory holds that should be considered for successful product development.

Latest from Nature Biotechnology